Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: ARNDT
Liczba odnalezionych rekordów: 3



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/3

Tytuł oryginału: Further arguments against including trisialo-Fe2-transferrin in carbohydrate-deficient transferrin (CDT): a study on male alcoholics and hazardous drinkers.
Autorzy: Arndt Torsten, Korzec Aleksander, B„r Marij, Kropf Jrgen
Źródło: Med. Sci. Monitor 2002: 8 (6) s.CR411-CR418, il., tab., bibliogr. 34 poz.
Sygnatura GBL: 313,278

Hasła klasyfikacyjne GBL:
  • psychiatria i psychologia

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: We attempted to determine whether including trisialo-Fe2-transferrin in carbohydrate-deficient transferrin (CDT) affects the diagnostic accuracy of CDT as a marker of chronic excessive alcohol intake. The criterion standard tests for the diagnosis of alcoholism and alcohol intake were the Composite International Diagnostic Interview (CIDI) and the Timeline-Followback (TLFB). The study groups (alcohol intake in each of the last 4 weeks before blood sampling) were comprised of 56 controls (ó 280 g/week, no alcoholism), 54 hazardous drinkers ( 280 g/week, no alcoholism), 63 alcoholics ( 280 g/week, alcoholism diagnosis). CDT analysis was performed with p.c.CDTri-TIA, which includes about 50 p.c. of trisialo-Fe2-transferrin in CDT, and ChronAl-col. D, which excludes this transferrin isoform from CDT. Depending on the cut-offs for the CTD/transferrin ratio (upper or lower limit of the test-specific borderlines) and on the patient group, the diagnostic sensitivity was 18.1 p.c. - 72 p.c. for p.c.CDTr-TIA, as opposed to 50.p.c. - 82.5 p.c. for ChronAlcol.D. The diagnostic accuracy was 62.8 p.c. - 78.5 p.c. for p.c.CDTri-TIA and 71.8 p.c. - 86.6 p.c. for ChronAlcol.D. The latter test consistently showed higher diagnostic sensitivity and accuracy than p.c. CDTri-TIA. The diagnostic specificity was 85.7 p.c. - 98.2 for p.c.CDTri-TIA and 91.1 p.c. - 92.2 p.c. for ChronAlcol.D. The areas under the ROC curve were 0.810 p.c. - 0.885 for p.c.CDTri-TIA and 0.867 p.c. - 0.896 for ChronAlcol.D. The present study and data from the literature indicate that including parts of trisialo-Fe2-transferrin by the p.c. CDRri-TIA test significantly reduces the diagnostic sensitivity and thus accuray of CDT as a marker of chronic excessive alcohol use.

    2/3

    Tytuł oryginału: A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gel.
    Autorzy: Werner J. A., Kehrl W., Płużańska A., Arndt O., Lavery K. M., Glaholm J., Dietz A., Dyckhoff G., Maune S., Stewart M. E., Orenberg E. K., Leavitt R. D.
    Źródło: Br. J. Cancer 2002: 87 (9) s.938-944, tab., bibliogr. 24 poz.
    Sygnatura GBL: 301,683

    Hasła klasyfikacyjne GBL:
  • toksykologia
  • farmacja
  • neurologia
  • onkologia

    Typ dokumentu:
  • praca kliniczna
  • praca opublikowana za granicą
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Patient with recurrent or refractory head and neck squamous cell carcinoma received cisplatin/epinephrine injectable gel or placebo gel injected directly into the clinically dominant tumour. The double-blind phase III trial comprised of up to 6 weekly treatments over 8 weeks, 4 weekly evaluation visits, and then monthy follow-up; open-label dosing began as needed after three blinded treatments. Tumour response was defined as complete (100 p.c. regression) or partial (50-99 p.c. regression) sustained for ň28 day, and patient benefit as attainment of paliative or preventive goals prospectively selected by investigators and patients. With cisplatin/epinephrine gel, 25 p.c. (14 out of 57) of tumours responded (16 p.c. complete regression, 96 partial regression), vs 3 p.c. (one out of 35, complete regression) with placebo (P = 0.007). Patient benefit was positively associated with target tumour response in the blinded period among cisplatn/epinephrine gel recipients (P = 0.024): 43 p.c. (six out of 14) of responders benefited, vs 12 p.c. (five out of 43) of non-responders. the most frequent adverse event was pain during injection and the next most frequent was local cytotoxic effects consistent with the gel's mode of action. systemic adverse events typical of intravenous cisplatin were uncommon. Intratumoral therapy with cisplatin/epinephrine gel provided safe, well-tolerated, effective palliative treatment for patients with locally advanced head and neck squamous cell carcinoma, who lack other satisfactory treatment options.

    3/3

    Tytuł oryginału: A prolonged time interval between blood sample collection and centrifugation causes an increase in serum carbohydrate-deficient transferrin.
    Autorzy: Arndt Torsten, Kropf Jrgen
    Źródło: Med. Sci. Monitor 2002: 8 (2) s.BR61-BR64, il., tab., bibliogr. 3 poz.
    Sygnatura GBL: 313,278

    Hasła klasyfikacyjne GBL:
  • hematologia

    Typ dokumentu:
  • praca doświadczalna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • in vitro

    Streszczenie angielskie: Carbohydrate-deficient transferrin (CDT) is used for the laboratory diagnosis of chronic alcohol abuse. Non-optimal preanalysis can cause an increase in CDT and false positive results. The aim of our study was to determine whether CDT results change over time between collection of the blood sample and centrifugation, and whether shipment of whole blood samples is a potential source of false positive CDT reports. Material/Methods: 152 blood samples were drawn from 38 persons (4 tubes per person, one venipuncture) and randomly assigned to 4 groups with different time intervals between blood sample collection and centrifugation (1h, 24h, 48h, 144h). CDT analysis was done using the ChronAlcol.D. assay. The statistical analysis was based on box-plots, ANOVA adn Kruskal-Wallis ANOVA. Results: The means and medians of CDT increased with the time of whole blood storage. ANOVA analysis of between-group differences was significant for mean CDT concentrations between 1 and 144 hours of whole blood storage. There was no correlation between CDT and free hemoglobin as a measure of hemolysis. An interference of hemolysis with CDT measurement can be excluded as the main cause of increased CDT results with whole blood storage time. Whether an in vitro degradation of the transferrin N-glycan chains causes the CDT increase should be evaluated by isoelectric foucusing of the transferrin isoforms in a further study. Conclusion: Storage or shipment of whole blood samples can shift initially normal CDT values to borderline and borderline to pathological CDT results.

    stosując format: